ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy

NCT05065554 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

IgM MGUS
Waldenstrom Macroglobulinemia
Neuropathy;Peripheral

Interventions

DRUG: Acalabrutinib
DRUG: Rituximab

Sponsor

Shayna Sarosiek, MD

Collaborators

[object Object]